股本结构
单位：万股
| 公告日期 | 2022-04-29 | 2022-04-11 | 2022-02-11 | 2022-03-17 | 2021-11-10 | 2021-11-10 |
|---|---|---|---|---|---|---|
| 证券总股本 | 490.23 | 489.87 | 17145.58 | 12020.58 | 11834.70 | 11811.48 |
| 普通股本 | 490.23 | 489.87 | 17145.58 | 12020.58 | 11834.70 | 11811.48 |
| 优先股 | 未披露 | 未披露 | 未披露 | 未披露 | 未披露 | 未披露 |
| 其他 | 未披露 | 未披露 | 未披露 | 未披露 | 未披露 | 未披露 |
| 变动日期 | 2022-04-25 | 2022-04-12 | 2022-02-10 | 2021-12-31 | 2021-11-05 | 2021-09-30 |
注释：中概股证券总股本=普通股股本/
存托凭证比例
历史变动
| 公告日期 | 变动后普通股本（万股） | 变动后优先股（万股） | 变动原因 | 变动日期 |
|---|---|---|---|---|
| 2022-04-29 | 490.23 | 未披露 | 定期报告 | 2022-04-25 |
| 2022-04-11 | 489.87 | 未披露 |
更多>>
Zosano Pharma Corporation (NASDAQ:ZSAN), a clinical-stage biopharmaceutical company, today announced that its Board of Directors has approved a 1-for-35 reverse stock split of the company’s common stock. The reverse stock split will become effective today, April 11, 2022.
|
2022-04-12 |
| 2022-02-11 | 17145.58 | 未披露 |
更多>>
1.Units offered by 51,250,000 Units.
2.The number of shares of common stock to be outstanding immediately after this offering as shown above is based on 118,114,793 shares of common stock outstanding as of September 30, 2021
|
2022-02-10 |
| 2022-03-17 | 12020.58 | 未披露 |
更多>>
From December 31, 2020 to December 31, 2021
Issuance of common stock in connection with at-the-market offering program, net
Issuance of common stock upon exercise of Series E warrants
Issuance of common stock upon exercise of Series C warrants
Release of restricted stock units
|
2021-12-31 |
| 2021-11-10 | 11834.70 | 未披露 | 定期报告 | 2021-11-05 |
| 2021-11-10 | 11811.48 | 未披露 |
更多>>
From June 30, 2021 to September 30, 2021
Issuance of common stock in connection with at-the-market offering, net
|
2021-09-30 |
| 2021-08-10 | 11559.07 | 未披露 | 定期报告 | 2021-08-06 |
| 2021-08-10 | 11332.93 | 未披露 |
更多>>
From March 31, 2021 to June 30, 2021
Issuance of common stock in connection with at-the-market offering, net
Release of restricted stock units
|
2021-06-30 |
| 2021-04-28 | 10672.84 | 未披露 | 定期报告 | 2021-04-15 |
| 2021-05-12 | 10637.28 | 未披露 |
更多>>
From January 1, 2021 To March 31, 2021
Issuance of common stock upon exercise of Series E warrants
Issuance of common stock upon exercise of Series C warrants
Issuance of common stock in connection with at-the-market offering, net
|
2021-03-31 |
| 2021-03-11 | 10628.99 | 未披露 | 定期报告 | 2021-03-09 |
| 2020-11-13 | 10206.62 | 未披露 |
更多>>
From June 30, 2020 to September 30, 2020
Issuance of common stock in connection with public offering, net
Issuance of common stock in connection with at-the-market offering, net
Issuance of common stock upon exercise of Series C warrants
Issuance of common stock upon exercise of Series E warrants
|
2020-09-30 |
| 2020-09-03 | 7318.24 | 未披露 |
更多>>
1.Common stock offered by the company 15,937,130 shares of common stock.
2.The number of shares of common stock to be outstanding immediately after this offering as shown above is based on 57,245,251 shares of common stock outstanding as of June 30, 2020.
|
2020-09-03 |
| 2020-08-31 | 7968.57 | 未披露 | 定期报告 | 2020-08-30 |
| 2020-08-06 | 6858.34 | 未披露 | 定期报告 | 2020-08-05 |
| 2020-08-06 | 5724.53 | 未披露 |
更多>>
from March 31, 2020 to June 30, 2020
Issuance of common stock in connection with at-the-market offering, net
Issuance of common stock upon exercise of Series C warrants
|
2020-06-30 |
| 2020-05-14 | 5436.16 | 未披露 |
更多>>
From January 1, 2020 to March 12, 2020
Issuance of common stock and Series E warrants in connection with registered direct offering, net
Issuance of common stock, Series C and Series D pre-funded warrants, in connection with public offering, net
Issuance of common stock upon exercise of Series D pre-funded warrants
Issuance of common stock upon exercise of Series C warrants
Issuance of common stock in connection with at-the-market offering, net
|
2020-03-12 |
| 2020-03-13 | 5433.89 | 未披露 | 定期报告 | 2020-03-09 |
| 2020-03-06 | 3013.43 | 未披露 | 定期报告 | 2020-03-06 |
| 2020-02-14 | 3053.85 | 未披露 |
更多>>
1.We are offering 10,146,154 Class A Units. Each Class A Unit consists of one share of common stock and one Series C Warrant to purchase one share of common stock (together with the share of common stock underlying such Series C Warrant).
|
2020-02-14 |
| 2020-03-13 | 2350.32 | 未披露 |
更多>>
From December 31, 2018 to December 31, 2019
Issuance of common stock in connection with public offering, net
Issuance of common stock in connection with at-the-market offering program, net
Issuance of common stock in connection with registered direct offering, net
|
2019-12-31 |
| 2019-12-02 | 2041.18 | 未披露 | 定期报告 | 2019-12-02 |
| 2019-11-14 | 1823.08 | 未披露 |
更多>>
From June 30, 2019 to September 30, 2019
Issuance of common stock in connection with At-the-Market offering
|
2019-09-30 |
| 2019-08-14 | 1772.30 | 未披露 |
更多>>
from March 31, 2019 to June 30, 2019
Issuance of common stock in connection with public offering
|
2019-06-30 |
| 2019-05-14 | 1772.30 | 未披露 | 定期报告 | 2019-05-10 |
| 2019-06-04 | 1697.30 | 未披露 | 定期报告 | 2019-04-30 |
| 2019-03-25 | 1197.30 | 未披露 |
更多>>
from December 31, 2017 to May 04, 2018
Issuance of common stock in connection with public offering
|
2018-05-04 |
| 2018-03-29 | 1197.30 | 未披露 |
更多>>
Common stock offered by us 10,000,000 shares
|
2018-04-03 |
| 2018-03-12 | 197.30 | 未披露 |
更多>>
from December 31, 2016 to January 26, 2018
Issuance of common stock in connection with public offering
Issuance of common stock in connection with exercise of warrants
Issuance of common stock in connection with equity line of credit
Issuance and release of restricted stock to certain board members as remuneration
Issuance of common stock upon the exercise of stock options
Accordingly, on January 23, 2018, the Board of Directors approved a 1-for-20 reverse stock split of the Common Stock (the “Reverse Stock Split”) and the filing of a Certificate of Amendment to the Amended and Restated Certificate of Incorporation of the Company to effectuate the Reverse Stock Split.As a result of the Reverse Stock Split, there will be approximately 2.0 million shares of Common Stock outstanding.
|
2018-01-26 |
| 2017-11-09 | 3946.09 | 未披露 | 定期报告 | 2017-11-03 |
| 2017-11-09 | 3923.34 | 未披露 | 定期报告 | 2017-09-30 |
| 2017-08-10 | 3923.01 | 未披露 | 定期报告 | 2017-08-04 |
| 2017-08-10 | 3922.01 | 未披露 | 定期报告 | 2017-06-30 |
| 2017-05-09 | 3920.01 | 未披露 | 定期报告 | 2017-05-04 |
| 2017-05-09 | 3919.06 | 未披露 | 定期报告 | 2017-03-31 |
| 2017-03-01 | 1945.03 | 未披露 | 定期报告 | 2017-02-20 |
| 2017-03-01 | 1681.60 | 未披露 |
更多>>
from December 31, 2015 to December 31, 2016
Issuance of common stock in connection with PIPE offering in August 2016, net of issuance costs
Redemption of common stock upon cashless exercise of stock options
Issuance of common stock to employees upon the exercise of stock options for cash at $1.81 to $2.28 per share
|
2016-12-31 |
| 2016-11-09 | 1681.60 | 未披露 | 定期报告 | 2016-11-03 |
| 2016-11-09 | 1681.60 | 未披露 | 定期报告 | 2016-09-30 |
| 2016-09-09 | 1681.60 | 未披露 | 定期报告 | 2016-08-19 |
| 2016-08-10 | 1201.60 | 未披露 | 定期报告 | 2016-08-01 |
| 2016-08-10 | 1201.60 | 未披露 | 定期报告 | 2016-06-30 |
| 2016-05-12 | 1201.25 | 未披露 | 定期报告 | 2016-05-02 |
| 2016-05-12 | 1196.80 | 未披露 | 定期报告 | 2016-03-31 |
| 2016-03-29 | 1196.79 | 未披露 | 定期报告 | 2016-03-10 |
| 2016-03-29 | 1196.70 | 未披露 |
更多>>
From December 31, 2014 to December 31, 2015
Issuance of common stock in connection with the Company’s initial public offering in January 2015, net of offering cost of $5.2 million
Issuance of common stock in connection with the private placement concurrent with the IPO in January 2015, net of offering cost of $0.5 million
Issuance of common stock upon the conversion of convertible bridge notes in January 2015
Issuance of common stock to employees upon the exercise of stock options for cash at $1.28 to $1.40 per share
Issuance and release of restricted stock to certain board members as remuneration
Issuance of common stock in connection with the exercise of the overallotment option of the IPO in February 2015, net of offering cost of $0.1 million
|
2015-12-31 |
| 2015-11-10 | 1196.70 | 未披露 | 定期报告 | 2015-11-05 |
| 2015-11-10 | 1196.70 | 未披露 | 定期报告 | 2015-09-30 |
| 2015-10-05 | 1196.70 | 未披露 | 定期报告 | 2015-09-25 |
| 2015-08-13 | 1196.54 | 未披露 | 定期报告 | 2015-08-04 |
| 2015-08-13 | 1194.50 | 未披露 | 定期报告 | 2015-06-30 |
| 2015-05-12 | 1194.10 | 未披露 | 定期报告 | 2015-05-06 |
| 2015-05-12 | 1193.20 | 未披露 | 定期报告 | 2015-03-31 |
| 2015-03-26 | 1193.20 | 未披露 | 定期报告 | 2015-03-10 |
| 2015-01-27 | 1181.61 | 未披露 |
更多>>
gives effect to a 1-for-4 reverse split of our common stock effected on July 11, 2014
|
2015-01-27 |
| 2015-01-09 | 516.51 | 未披露 | 定期报告 | 2014-12-31 |
| 2014-12-10 | 514.04 | 未披露 | 定期报告 | 2014-10-31 |
| 2014-12-10 | 514.00 | 未披露 | 定期报告 | 2014-09-30 |
| 2014-07-16 | 513.81 | 未披露 |
更多>>
a 1-for-4 reverse split of our common stock effected on July 11, 2014
|
2014-07-14 |
| 2014-06-24 | 2055.23 | 未披露 | 定期报告 | 2014-06-15 |
| 2014-06-24 | 2042.70 | 未披露 | 定期报告 | 2014-03-31 |
Zosano Pharma Corporation (NASDAQ:ZSAN), a clinical-stage biopharmaceutical company, today announced that its Board of Directors has approved a 1-for-35 reverse stock split of the company’s common stock. The reverse stock split will become effective today, April 11, 2022.
1.Units offered by 51,250,000 Units.
2.The number of shares of common stock to be outstanding immediately after this offering as shown above is based on 118,114,793 shares of common stock outstanding as of September 30, 2021
From December 31, 2020 to December 31, 2021
Issuance of common stock in connection with at-the-market offering program, net
Issuance of common stock upon exercise of Series E warrants
Issuance of common stock upon exercise of Series C warrants
Release of restricted stock units
From June 30, 2021 to September 30, 2021
Issuance of common stock in connection with at-the-market offering, net
From March 31, 2021 to June 30, 2021
Issuance of common stock in connection with at-the-market offering, net
Release of restricted stock units
From January 1, 2021 To March 31, 2021
Issuance of common stock upon exercise of Series E warrants
Issuance of common stock upon exercise of Series C warrants
Issuance of common stock in connection with at-the-market offering, net
From June 30, 2020 to September 30, 2020
Issuance of common stock in connection with public offering, net
Issuance of common stock in connection with at-the-market offering, net
Issuance of common stock upon exercise of Series C warrants
Issuance of common stock upon exercise of Series E warrants
1.Common stock offered by the company 15,937,130 shares of common stock.
2.The number of shares of common stock to be outstanding immediately after this offering as shown above is based on 57,245,251 shares of common stock outstanding as of June 30, 2020.
from March 31, 2020 to June 30, 2020
Issuance of common stock in connection with at-the-market offering, net
Issuance of common stock upon exercise of Series C warrants
From January 1, 2020 to March 12, 2020
Issuance of common stock and Series E warrants in connection with registered direct offering, net
Issuance of common stock, Series C and Series D pre-funded warrants, in connection with public offering, net
Issuance of common stock upon exercise of Series D pre-funded warrants
Issuance of common stock upon exercise of Series C warrants
Issuance of common stock in connection with at-the-market offering, net
1.We are offering 10,146,154 Class A Units. Each Class A Unit consists of one share of common stock and one Series C Warrant to purchase one share of common stock (together with the share of common stock underlying such Series C Warrant).
From December 31, 2018 to December 31, 2019
Issuance of common stock in connection with public offering, net
Issuance of common stock in connection with at-the-market offering program, net
Issuance of common stock in connection with registered direct offering, net
From June 30, 2019 to September 30, 2019
Issuance of common stock in connection with At-the-Market offering
from March 31, 2019 to June 30, 2019
Issuance of common stock in connection with public offering
from December 31, 2017 to May 04, 2018
Issuance of common stock in connection with public offering
Common stock offered by us 10,000,000 shares
from December 31, 2016 to January 26, 2018
Issuance of common stock in connection with public offering
Issuance of common stock in connection with exercise of warrants
Issuance of common stock in connection with equity line of credit
Issuance and release of restricted stock to certain board members as remuneration
Issuance of common stock upon the exercise of stock options
Accordingly, on January 23, 2018, the Board of Directors approved a 1-for-20 reverse stock split of the Common Stock (the “Reverse Stock Split”) and the filing of a Certificate of Amendment to the Amended and Restated Certificate of Incorporation of the Company to effectuate the Reverse Stock Split.As a result of the Reverse Stock Split, there will be approximately 2.0 million shares of Common Stock outstanding.
from December 31, 2015 to December 31, 2016
Issuance of common stock in connection with PIPE offering in August 2016, net of issuance costs
Redemption of common stock upon cashless exercise of stock options
Issuance of common stock to employees upon the exercise of stock options for cash at $1.81 to $2.28 per share
From December 31, 2014 to December 31, 2015
Issuance of common stock in connection with the Company’s initial public offering in January 2015, net of offering cost of $5.2 million
Issuance of common stock in connection with the private placement concurrent with the IPO in January 2015, net of offering cost of $0.5 million
Issuance of common stock upon the conversion of convertible bridge notes in January 2015
Issuance of common stock to employees upon the exercise of stock options for cash at $1.28 to $1.40 per share
Issuance and release of restricted stock to certain board members as remuneration
Issuance of common stock in connection with the exercise of the overallotment option of the IPO in February 2015, net of offering cost of $0.1 million
gives effect to a 1-for-4 reverse split of our common stock effected on July 11, 2014
a 1-for-4 reverse split of our common stock effected on July 11, 2014